- Home
- CERO vs MEGL Comparison
CERO vs MEGL Comparison
Compare CERO & MEGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CERO
- MEGL
- Stock Information
- Founded
- CERO 2017
- MEGL 2016
- Country
- CERO United States
- MEGL Hong Kong
- Employees
- CERO N/A
- MEGL N/A
- Industry
- CERO
- MEGL Finance: Consumer Services
- Sector
- CERO
- MEGL Finance
- Exchange
- CERO Nasdaq
- MEGL Nasdaq
- Market Cap
- CERO 3.5M
- MEGL 6.3M
- IPO Year
- CERO N/A
- MEGL 2022
- Fundamental
- Price
- CERO $8.90
- MEGL $1.54
- Analyst Decision
- CERO Strong Buy
- MEGL
- Analyst Count
- CERO 2
- MEGL 0
- Target Price
- CERO $45.00
- MEGL N/A
- AVG Volume (30 Days)
- CERO 3.3M
- MEGL 220.7K
- Earning Date
- CERO 08-13-2025
- MEGL 07-22-2025
- Dividend Yield
- CERO N/A
- MEGL N/A
- EPS Growth
- CERO N/A
- MEGL N/A
- EPS
- CERO N/A
- MEGL N/A
- Revenue
- CERO N/A
- MEGL $1,645,862.00
- Revenue This Year
- CERO N/A
- MEGL N/A
- Revenue Next Year
- CERO N/A
- MEGL N/A
- P/E Ratio
- CERO N/A
- MEGL N/A
- Revenue Growth
- CERO N/A
- MEGL N/A
- 52 Week Low
- CERO $6.71
- MEGL $1.02
- 52 Week High
- CERO $895.40
- MEGL $5.52
- Technical
- Relative Strength Index (RSI)
- CERO 46.23
- MEGL 47.62
- Support Level
- CERO $8.50
- MEGL $1.56
- Resistance Level
- CERO $9.73
- MEGL $1.65
- Average True Range (ATR)
- CERO 1.20
- MEGL 0.08
- MACD
- CERO -0.01
- MEGL -0.02
- Stochastic Oscillator
- CERO 14.54
- MEGL 6.06
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.
About MEGL Magic Empire Global Limited
Magic Empire Global Ltd is a financial services provider in Hong Kong which principally engage in the provision of corporate finance advisory services and underwriting services. The companys offerings mainly comprise of IPO sponsorship services, Financial advisory and independent financial advisory services, Compliance advisory services, Underwriting services, Corporate service.